SMIFH2
Based on 10 publication(s) in Google Scholar
SMIFH2 is a formin specific inhibitor. SMIFH2 inhibits actin polymerization by Formins and affects the actin cytoskeleton.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.08%
- No. CAS: 340316-62-3
- Fòrmula: C15H9BrN2O3S
- Peso molecular:377.21
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Cytoskeleton Compound Library
HY-L060
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) SMIFH2
More- Nature. 2026 Jun;654(8118):495-503. [Abstract]
- Nat Commun. 2025 Aug 5;16(1):7190. [Abstract]
- Adv Sci (Weinh). 2026 Mar;13(16):e13310. [Abstract]
- Int J Biol Macromol. 2025 Jan 20:140112. [Abstract]
- Theriogenology. 2023 Nov:211:40-48. [Abstract]
- Virology. 2024 Dec:600:110233. [Abstract]
- Dev Comp Immunol. 2026 May:178:105593. [Abstract]
- Biomed Pharmacother. 2026 Feb:195:119061. [Abstract]
- bioRxiv. 2025 Aug 05.
- bioRxiv. 2025 April 23.
Customer Validation & Images
-
Flow Cytometry
-
IF
-
RT-PCR
-
WB
-
IF
Actividad biológica
Formin[1]
SMIFH2 (25 uM; 1-16 hours) induces dynamic cytoskeletal remodelling in U2OS cells[1].
SMIFH2 (25 μM) reduces p300, mDia2 and p53 levels in a proteasome-independent manner[1].
SMIFH2 reduces expression and activity of p53 through a post-transcriptional, proteasome-independent mechanism that influences remodelling of the cytoskeleton[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:293T, A375, U2OS, and MDA-MB-231 cells
-
Concentration:25 μM
-
Incubation Time:5 hours for 293T, U2OS, MDA-MB-231 cells; 2.5 hours for A375 cells
-
Result:Downregulated mDia2, p53 and p300 protein levels.
Chemical Information
-
No. CAS 340316-62-3
-
Appearance Solid
-
Peso molecular 377.21
-
Fòrmula C15H9BrN2O3S
-
Color Light yellow to green yellow
-
SMILES
O=C(/C(C(N1C2=CC=CC(Br)=C2)=O)=C\C3=CC=CO3)NC1=S
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jun;654(8118):495-503. PMID: 42056510 -
Nat Commun
Promoting implant osseointegration via the osteoblast-selective β-amino acid polymer strategy. [Abstract]2025 Aug 5;16(1):7190. PMID: 40764473 -
Adv Sci (Weinh)
2026 Mar;13(16):e13310. PMID: 41589654 -
Int J Biol Macromol
Host factor DIAPH1 regulates pseudorabivirus replication by modulating the dynamics of cytoskeleton. [Abstract]2025 Jan 20:140112. PMID: 39842589
SMIFH2 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan 20:140112. [Abstract]
SMIFH2 (1-50 μM; 4 h) treatment resulted in a decrease in PRV-GFP proliferation, as indicated by a lower percentage of GFP-positive cells in PK-15 cells.
SMIFH2 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan 20:140112. [Abstract]
SMIFH2 (5-50 μM; 4 h) caused dose-dependent inhibition of PRV replication in PK-15 cells.
SMIFH2 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan 20:140112. [Abstract]
SMIFH2 (1-50 μM; 4 h) inhibited DIAPH1 and diminished the PRV viral progeny production.
SMIFH2 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan 20:140112. [Abstract]
SMIFH2 (50 μM; 4 h) decreased the level of acetylated-α-tubulin in PK-15 cells.
SMIFH2 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan 20:140112. [Abstract]
SMIFH2 (50 μM; 4 h) decreased actin levels and the formation of thick, long actin stress fibers, resulting in more thin and short microfilaments in PK-15 cells.
-
Theriogenology
The formins inhibitor SMIFH2 inhibits the cytoskeleton dynamics and mitochondrial function during goat oocyte maturation. [Abstract]2023 Nov:211:40-48. PMID: 37562190 -
Virology
2024 Dec:600:110233. PMID: 39255726 -
Dev Comp Immunol
Development of monoclonal antibodies against IgM of common carp (Cyprinus carpio) and analysis of phagocytosis by mIgM+ B lymphocytes. [Abstract]2026 May:178:105593. PMID: 41881180 -
Biomed Pharmacother
2026 Feb:195:119061. PMID: 41604889 -
-
Solvente y solubilidad
DMSO : 125 mg/mL (331.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.51 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6510 mL | 13.2552 mL | 26.5104 mL | 66.2761 mL |
| 5 mM | 0.5302 mL | 2.6510 mL | 5.3021 mL | 13.2552 mL | |
| 10 mM | 0.2651 mL | 1.3255 mL | 2.6510 mL | 6.6276 mL | |
| 15 mM | 0.1767 mL | 0.8837 mL | 1.7674 mL | 4.4184 mL | |
| 20 mM | 0.1326 mL | 0.6628 mL | 1.3255 mL | 3.3138 mL | |
| 25 mM | 0.1060 mL | 0.5302 mL | 1.0604 mL | 2.6510 mL | |
| 30 mM | 0.0884 mL | 0.4418 mL | 0.8837 mL | 2.2092 mL | |
| 40 mM | 0.0663 mL | 0.3314 mL | 0.6628 mL | 1.6569 mL | |
| 50 mM | 0.0530 mL | 0.2651 mL | 0.5302 mL | 1.3255 mL | |
| 60 mM | 0.0442 mL | 0.2209 mL | 0.4418 mL | 1.1046 mL | |
| 80 mM | 0.0331 mL | 0.1657 mL | 0.3314 mL | 0.8285 mL | |
| 100 mM | 0.0265 mL | 0.1326 mL | 0.2651 mL | 0.6628 mL |
SMIFH2 Related Classifications
HY-16931 Related Classifications
Powered by Bioz